SKM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- SKM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- SKM-1
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.514
- MYC_TARGETS_V2+0.479
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- E2F_TARGETS+0.352
- MYC_TARGETS_V1+0.261
- DNA_REPAIR+0.261
- G2M_CHECKPOINT+0.221
- INTERFERON_GAMMA_RESPONSE+0.185
- COMPLEMENT+0.166
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- PROTEIN_SECRETION-0.327
- TGF_BETA_SIGNALING-0.276
- TNFA_SIGNALING_VIA_NFKB-0.247
- COAGULATION-0.220
- UV_RESPONSE_DN-0.147
- XENOBIOTIC_METABOLISM-0.122
- APOPTOSIS-0.122
- HYPOXIA-0.118
- P53_PATHWAY-0.087
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AML193_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.867 |
| 2 | THP1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.838 |
| 3 | KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.808 |
| 4 | U937_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.787 |
| 5 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.774 |
| 6 | TCGA-A2-A0EQ-01A-11R-A034-07 | — | C | 0.765 |
| 7 | KCL22_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.759 |
| 8 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.756 |
| 9 | 20060324.TNBC | — | D | 0.751 |
| 10 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.514 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.479 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.352 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.261 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.261 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.221 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.185 | Idelalisib | — uncovered |
| COMPLEMENT | 0.166 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.141 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.135 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.127 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.127 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.122 | Cobimetinib | — uncovered |
| PEROXISOME | 0.118 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.109 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.108 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.095 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.089 | Idelalisib | — uncovered |